Semaglutide is the compound that turned GLP-1 receptor agonism from a diabetes therapy into the reference point for an entire weight-management category. Before STEP 1, single-receptor GLP-1 drugs produced modest single-digit weight loss. STEP 1 reported 14.9% mean loss at 68 weeks on the 2.4 mg dose, an order-of-magnitude jump in what a GLP-1 compound was understood to be capable of. [1] This is the complete, evidence-first guide: what it is, why it works, what the data actually show, and what a research buyer needs to know.
It is written for research and educational purposes. Everything here reports what the published clinical literature describes; none of it is medical advice, and the semaglutide discussed here is a research compound, not the approved pharmaceutical product dispensed as Ozempic or Wegovy.
Semaglutide at a glance
| Attribute | Detail |
|---|---|
| Compound | Semaglutide |
| Class | Single agonist: GLP-1 receptor |
| Headline result | 14.9% mean weight loss, 2.4 mg, 68 weeks (STEP 1) |
| Cadence | Once weekly, subcutaneous (an oral daily tablet also exists) |
| Half-life | ~7 days |
| Main side effects | Dose-dependent GI (nausea, diarrhea, constipation, vomiting) |
| Status | The molecule is FDA-approved as Ozempic/Wegovy; sold here as a research compound, not for human use |
What semaglutide is
Semaglutide is a modified version of human GLP-1, the incretin hormone released from the gut after eating that signals satiety and helps regulate blood glucose. Native GLP-1 is degraded within minutes by the enzyme DPP-4 and cleared by the kidneys, which makes it useless as a drug on its own. Semaglutide solves that with two changes to the peptide backbone: amino-acid substitutions that resist DPP-4 breakdown, and a fatty-diacid side chain that binds the molecule to circulating albumin. [2] Together those changes stretch its functional half-life from minutes to roughly a week, which is what makes once-weekly dosing possible.
That single design choice, the albumin-binding side chain, is the same engineering approach later reused and extended in tirzepatide and retatrutide, which is why all three compounds share a once-weekly cadence despite activating different numbers of receptors.
How semaglutide works: the GLP-1 mechanism
| Effect | Mechanism |
|---|---|
| Appetite suppression | Acts on hypothalamic and hindbrain circuits that regulate hunger and satiety |
| Slowed gastric emptying | Food stays in the stomach longer, extending the feeling of fullness |
| Glucose-dependent insulin secretion | Increases insulin release only when glucose is elevated, which limits hypoglycemia risk |
| Reduced glucagon secretion | Lowers the liver's glucose output between meals |
All of semaglutide's effects, weight loss and glycemic control alike, run through this single receptor. That is the defining fact of the compound and the reason it is the baseline every newer multi-receptor agonist is measured against. Appetite suppression and slowed gastric emptying are the two mechanisms most responsible for reduced caloric intake, while the glucose-dependent insulin effect is why the drug class improves blood sugar without the hypoglycemia risk of older glucose-lowering therapies. [2]
Because semaglutide works on a single lever, its ceiling is lower than a compound that adds GIP or glucagon activity on top of the same GLP-1 foundation. That single-lever versus multi-lever distinction is the whole story behind the comparison numbers later in this guide.
What the STEP trials showed
The STEP program is the anchor of everything known about semaglutide's weight-management efficacy. It ran four pivotal trials, each isolating a different question, and together they are the most complete efficacy picture behind any single GLP-1 compound.
| Trial | Population | Design | Result |
|---|---|---|---|
| STEP 1 | Adults with obesity or overweight, no diabetes | Semaglutide 2.4 mg vs placebo, 68 weeks | 14.9% mean weight loss [1] |
| STEP 2 | Adults with type 2 diabetes | Semaglutide 2.4 mg vs 1.0 mg vs placebo, 68 weeks | 9.6% mean weight loss at 2.4 mg [3] |
| STEP 3 | Adults with obesity or overweight | Semaglutide 2.4 mg plus intensive behavioral therapy, 68 weeks | 16.0% mean weight loss [4] |
| STEP 4 | Adults with obesity or overweight | 20-week run-in on semaglutide, then randomized to continue vs switch to placebo | Continuers reached roughly 17.4% total loss; those switched to placebo regained weight [5] |
STEP 1 is the headline: 2.4 mg of semaglutide, dosed once weekly, produced a mean 14.9% reduction in body weight at 68 weeks, against roughly 2.4% on placebo. [1] That is the figure that established semaglutide, and by extension the whole GLP-1 weight-management class, as a category distinct from prior anti-obesity pharmacotherapy.
STEP 2 matters because it studied semaglutide in people with type 2 diabetes, a population that historically loses less weight on GLP-1 therapy than people without diabetes. The 9.6% mean result at 2.4 mg, versus 3.4% on placebo, confirmed the effect held in that harder-to-treat population, just at a smaller magnitude. [3]
STEP 3 tested what happens when semaglutide is paired with intensive behavioral therapy (structured counseling, a reduced-calorie diet, and increased physical activity). The result, 16.0% mean loss, was the highest of the STEP program, suggesting the drug and behavioral support are additive rather than the drug alone doing all the work. [4]
STEP 4 answers a different, arguably more practical question: what happens if you stop. All participants ran in for 20 weeks on semaglutide, reaching a mean of 10.6% loss, then were randomized to either continue or switch to placebo. Those who continued kept losing, reaching roughly 17.4% total loss by week 68. Those switched to placebo regained a substantial share of the weight they had lost. [5] That result is the trial evidence behind a fact this guide returns to below: semaglutide's effect is maintained by continued dosing, not banked permanently after a course of treatment.
Semaglutide and diabetes: the SUSTAIN program
Semaglutide's regulatory story began in diabetes, not obesity, and the SUSTAIN trial program is what built that case. Across the SUSTAIN 1 through 5 trials, semaglutide reduced HbA1c (a 3-month average blood glucose marker) by roughly 1.5 to 1.8 percentage points depending on dose and comparator, outperforming several existing standard-of-care diabetes therapies head-to-head. [6]
The most consequential single trial in that program is SUSTAIN-6, a cardiovascular outcomes trial in people with type 2 diabetes at elevated cardiovascular risk. It reported a 26% relative risk reduction in major adverse cardiovascular events (a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) versus placebo, added on top of standard care. [6] That finding is part of why the GLP-1 class is studied for effects well beyond glucose and weight: the same receptor that governs appetite and insulin secretion appears to influence vascular and cardiac outcomes as well.
| STEP program | SUSTAIN program | |
|---|---|---|
| Primary question | Weight loss in obesity/overweight | Glycemic control and cardiovascular risk in type 2 diabetes |
| Typical dose studied | 2.4 mg (weight-management ceiling) | 0.5 mg and 1.0 mg (glycemic-control range) |
| Headline figure | 14.9% mean weight loss (STEP 1) [1] | 26% relative MACE risk reduction (SUSTAIN-6) [6] |
The dose difference in that table explains a question that comes up constantly: why does the same drug seem to produce different weight-loss numbers depending on the source. STEP used the higher, weight-management dose; most of SUSTAIN used lower, glycemic-control doses where weight loss was a secondary rather than primary outcome.
Your weight-loss timeline: how long does semaglutide take to work
The STEP trial numbers are measured at 68 weeks, but the path there has a predictable shape, and understanding it is what keeps a research protocol from being abandoned too early.
| Phase | What tends to happen |
|---|---|
| Weeks 1 to 4 (0.25 mg, sub-therapeutic) | This dose exists mainly to reduce GI-effect onset; little weight change is expected. |
| Weeks 5 to 16 (titration through 0.5, 1.0, 1.7 mg) | Appetite suppression builds step by step as each dose layers on the last. |
| Weeks 16 to 20 (2.4 mg reached, steady state approaching) | Plasma levels approach steady state around 4 to 5 weeks after the final step up; effects become consistent. |
| Weeks 20 to 68 (sustained loss) | Weight loss continues at a slowing but still meaningful rate toward the 68-week trial endpoint. [1] |
The most common misread, the same one that shows up across the entire GLP-1 class, is judging the compound during the first month, while the dose is still at or near the sub-therapeutic 0.25 mg starting step. The titration schedule is deliberately slow, so early weeks systematically understate the eventual effect. STEP 1's own numbers were not read until 68 weeks for exactly this reason.
Half-life and dosing cadence: how long does semaglutide stay in your system
Semaglutide's roughly 7-day half-life is what makes once-weekly dosing viable, and it is very close to retatrutide's roughly 6-day half-life, which is why the two compounds are often described as pharmacokinetically similar even though their receptor mechanisms differ sharply. [2]
Because of that half-life, plasma levels build gradually with each weekly dose and reach steady state in roughly 4 to 5 weeks, the same window most GLP-1 class compounds share. After the last dose, semaglutide is largely cleared from circulation in about 5 weeks (roughly five half-lives). [2] A single missed dose lowers exposure but does not zero it out, since the prior week's dose is still circulating.
Dosing and titration: the 0.25 mg to 2.4 mg schedule
The clinical program did not start at the 2.4 mg dose that produced STEP 1's headline result. It climbed there stepwise, and the schedule below is reported as trial information, not a dosing recommendation.
| Step | Dose | Approximate duration | Purpose |
|---|---|---|---|
| 1 | 0.25 mg once weekly | 4 weeks | Sub-therapeutic; allows the GI system to adapt before dose increases |
| 2 | 0.5 mg once weekly | 4 weeks | First clinically active step |
| 3 | 1.0 mg once weekly | 4 weeks | Intermediate step |
| 4 | 1.7 mg once weekly | 4 weeks | Approaches the target dose |
| 5 | 2.4 mg once weekly | Ongoing (maintenance) | The dose studied for weight management in STEP 1 [1] |
Each step exists to let the body adjust to a new exposure level before the next increase, the same tolerability logic used across the GLP-1 class. Skipping steps or escalating faster than the studied schedule was not the protocol used in the trials that produced these results, which matters because the efficacy and the tolerability data were both generated under this specific pacing.
Oral vs injectable semaglutide
Semaglutide is the only compound in this class with a clinically studied oral form, which makes the injectable-versus-oral question specific to this molecule rather than to the GLP-1 category in general.
| Attribute | Injectable (subcutaneous) | Oral (tablet) |
|---|---|---|
| Cadence | Once weekly | Once daily |
| Bioavailability | High (direct absorption) | Low; co-formulated with an absorption enhancer and taken fasted |
| Weight-loss data | 14.9% at 2.4 mg, 68 weeks (STEP 1) [1] | 17.4% at 50 mg, 68 weeks (OASIS 1) [7] |
| Administration | Subcutaneous injection | Tablet, fasted, with a small amount of water, no food for 30 minutes after |
The oral form works differently at the pharmacology level: semaglutide is a peptide, and peptides are normally destroyed by stomach acid and digestive enzymes before they can be absorbed. The oral tablet is co-formulated with an absorption enhancer that transiently raises local pH and protects a fraction of the dose long enough to cross the stomach lining, which is why oral bioavailability is low and why the tablet has to be taken fasted, with minimal water, well before food. [7]
The OASIS 1 trial, which studied a higher 50 mg once-daily oral dose specifically for weight management, reported 17.4% mean weight loss at 68 weeks, a result in the same range as the injectable 2.4 mg dose in STEP 1. [7] That is a meaningful finding: it shows the oral route can match the injectable route's efficacy at a sufficiently high dose, even though the administration requirements (fasting, timing, and a substantially higher milligram dose to compensate for low absorption) are more demanding.
Semaglutide vs tirzepatide vs retatrutide
The single most common question researchers bring to this compound is how it stacks up against the newer multi-receptor agonists. On published mean weight-loss numbers, semaglutide is the reference point the newer compounds are compared against, not the frontier.
The stepwise pattern, more receptor coverage tracking with more mean weight loss, is exactly what the sequential development of this class predicts, and it is why semaglutide is the natural baseline against which every newer compound's added receptor activity gets measured. [8] [9] It is not proof that receptor count alone drives the difference (these are separate trials with separate populations and durations), but the pattern is consistent enough that it shapes how researchers frame each new compound's value proposition.
For the deeper dive on either comparison specifically, see semaglutide vs retatrutide and tirzepatide vs semaglutide.
Is semaglutide the same as Ozempic and Wegovy?
The molecule is identical; the product is not. Ozempic and Wegovy are both FDA-approved brand names for semaglutide, made by the same manufacturer and dispensed by prescription through a pharmacy. Ozempic is approved for type 2 diabetes, dosed up to 2.0 mg weekly; Wegovy is approved for chronic weight management, titrated to the 2.4 mg dose studied in STEP 1. [1]
| Ozempic / Wegovy | Research compound | |
|---|---|---|
| Molecule | Semaglutide | Semaglutide |
| Regulatory status | FDA-approved prescription drug | Not approved for human use |
| Distribution | Pharmacy, by prescription | Research-compound market |
| Label | Approved indication and dosing | Research-use / not-for-human-use statement |
| Quality assurance | Enforced pharmaceutical GMP, per-patient regulatory oversight | Batch-matched certificate of analysis, ideally independently verified |
The distinction is regulatory and commercial, not chemical: the active molecule is the same GLP-1 agonist described throughout this guide. What differs is everything that surrounds it, from the manufacturing standard to the label to how it reaches the end user. Anyone comparing "semaglutide" figures across sources should keep that distinction in view, because trial data (STEP, SUSTAIN, OASIS) describe the molecule's biology, while the FDA-approved and research-compound designations describe two separate products built on that same biology.
Side effects reported in trials
Semaglutide's side-effect profile is dominated by gastrointestinal effects, the class signature shared by every GLP-1 agonist. STEP and SUSTAIN both reported nausea, diarrhea, constipation, and vomiting as the most common effects, dose-dependent and concentrated during dose escalation, then easing at a stable dose. [1] [6]
| Effect | Pattern reported in trials |
|---|---|
| Nausea | Most common; peaks during dose escalation, especially the 0.25 to 1.0 mg steps |
| Diarrhea | Common; dose-dependent |
| Constipation | Common; can persist longer than nausea for some participants |
| Vomiting | Less common than nausea; also dose-dependent |
| Injection-site reactions | Mild and localized, reported infrequently |
As with every figure in this guide, incidence and severity are trial-reported findings describing study populations, not a prediction for any individual research subject.
Why the GI effects happen and why they fade
The gastrointestinal effects are a direct extension of the mechanism, not an incidental side reaction. GLP-1 receptor activation slows gastric emptying, which is part of how the compound suppresses appetite, and the same slowing produces nausea when exposure rises too abruptly. That is why effects concentrate during the early titration steps, when plasma levels are climbing fastest, and why they settle once the dose (and plasma level) stabilizes. [1] The stepwise schedule described above exists specifically to give the gut time to adapt at each level before the next increase; none of this is dosing advice, it is the trial-reported rationale for why the titration schedule looks the way it does.
Is semaglutide safe: myths and misconceptions
Semaglutide's rapid rise in public awareness produced an unusually large volume of secondhand claims, several of which are worth addressing directly against the trial and regulatory record.
| Claim | What the record shows |
|---|---|
| "Semaglutide causes thyroid cancer" | A boxed warning exists because of thyroid C-cell tumors observed in rodent studies at doses far exceeding human exposure; a causal link in humans has not been established, and the labeling reflects an animal-model precaution rather than a confirmed human risk. |
| "Semaglutide is a steroid" | No. It is a peptide hormone analog (a modified GLP-1), structurally and mechanistically unrelated to steroid hormones. |
| "The weight comes back the moment you stop" | STEP 4 showed exactly this pattern: participants who continued dosing kept losing weight, while those switched to placebo regained a substantial share of what they had lost, which is trial evidence that continued dosing, not a fixed course, is what maintains the effect. [5] |
| "It's basically insulin" | No. Semaglutide activates the GLP-1 receptor and increases insulin secretion only when glucose is elevated (glucose-dependent), which is mechanistically distinct from injecting insulin directly. |
The honest, evidence-grounded read is that semaglutide's most-cited risks are real regulatory precautions worth understanding, not evidence of a hidden danger the trials failed to detect. Reading the labeling and the primary trial literature directly, rather than secondhand claims, is the more reliable way to evaluate any of these questions.
Is semaglutide right for your research
Semaglutide is best understood as the field's most extensively characterized single-receptor GLP-1 compound. Between STEP, SUSTAIN, and years of post-marketing data on the approved brands, more is known about its biology, dosing behavior, and long-run safety signal than about any newer multi-receptor agonist. [1] [6] For a research program, that maturity is the appeal: it is the compound to study as an established single-receptor reference, or as the baseline against which a multi-agonist's added receptor activity is measured. It is not the compound with the largest reported efficacy signal, because that frontier now belongs to tirzepatide and retatrutide.
How to get semaglutide (and what to look for)
Because the semaglutide sold here is supplied as a research compound rather than the approved pharmaceutical product, sourcing quality is the decisive variable, exactly as it is for retatrutide and tirzepatide. The single most important thing to verify is a batch-matched certificate of analysis tied to a specific lot: mass by HPLC, identity by mass spectrometry, a measured purity figure, and a characterized impurity profile, ideally confirmed by independent third-party testing rather than the manufacturer's own numbers alone.
Our full standard for evaluating a supplier is documented in how we vet a new manufacturer. Modern Bio's semaglutide ships with a batch-matched COA on every vial.
Reconstitution basics
Semaglutide ships as a lyophilized powder and is reconstituted with bacteriostatic water before use. The water is added slowly down the vial wall, swirled (never shaken), and stored refrigerated with the date labeled. The concentration created determines what each dose measures, so it is worth setting deliberately. The complete procedure is in how to reconstitute peptides with bacteriostatic water.
Common mistakes that muddy results
- Reading the first month as the verdict. The 0.25 mg starting step is sub-therapeutic by design; early weeks systematically understate the compound.
- Escalating faster than the studied schedule. The stepwise titration exists to manage GI tolerability; rushing it is a common reason a protocol is abandoned during the ramp.
- Treating a fixed course as permanent. STEP 4 showed the effect fades without continued dosing; planning around a finite "course" misreads what the withdrawal data actually showed. [5]
- Sloppy reconstitution. Foaming, shaking, and freeze-thaw cycles degrade the peptide before it reaches the model system, adding variability that looks like a compound effect.
- Sourcing on price alone. A low price often reflects skipped independent testing, the exact verification that keeps the label consistent with the vial.
How to maximize a research protocol
The trial data point to a few conditions under which the compound performs as studied: consistent weekly cadence, a full titration through each dose step rather than a rushed climb, and enough time (past the 4 to 5 week steady-state window, and toward the 68-week horizon where STEP's numbers were measured) before drawing conclusions. Reproducible handling, meaning dated vials, gentle reconstitution, and cold storage, is what makes any of the downstream data interpretable.
Frequently asked questions
- What is semaglutide?
- Semaglutide is a single-receptor GLP-1 agonist, a lab-modified version of the human incretin hormone GLP-1 engineered for a long circulating half-life. In the STEP 1 trial it produced 14.9% mean body-weight loss at 68 weeks on the 2.4 mg dose, the result that established the modern GLP-1 weight-management category.
- How much weight did semaglutide produce in trials?
- In STEP 1 (NEJM, 2021), the 2.4 mg group lost a mean of 14.9% of body weight at 68 weeks, versus roughly 2.4% on placebo. STEP 3, which paired semaglutide with intensive behavioral therapy, reached 16.0%. For comparison, tirzepatide reached roughly 21% and retatrutide roughly 24% in their own trials.
- How is semaglutide different from tirzepatide and retatrutide?
- Receptor coverage. Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. Retatrutide activates three, GLP-1, GIP, and glucagon. Semaglutide is the single-receptor reference point the newer multi-agonists are measured against.
- How is semaglutide dosed?
- As a once-weekly subcutaneous injection, its roughly 7-day half-life supports that cadence. The clinical program escalated the dose stepwise over about 16 to 20 weeks, from a 0.25 mg starting dose up to the 2.4 mg dose studied for weight management. An oral tablet form exists as well, dosed daily.
- What are semaglutide's side effects?
- The most common effects reported in trials were gastrointestinal, including nausea, diarrhea, constipation, and vomiting, all dose-dependent and concentrated during dose escalation, then easing at a stable dose.
- How long does semaglutide stay in your system?
- With a roughly 7-day half-life, semaglutide is largely cleared about 5 weeks after the last dose, and plasma levels reach steady state in about the same window on weekly dosing.
- Is semaglutide the same as Ozempic and Wegovy?
- The molecule is the same. Ozempic and Wegovy are FDA-approved brand names for semaglutide, dispensed by prescription through a pharmacy. The semaglutide sold as a research compound is the same molecule supplied unbranded, for laboratory and research use, not as the approved pharmaceutical product.
- What should I look for when sourcing semaglutide?
- A batch-matched certificate of analysis tied to a specific lot, mass by HPLC, identity by mass spectrometry, a measured purity figure, and a characterized impurity profile, ideally backed by independent third-party testing rather than only the manufacturer's own numbers.
Glossary
- GLP-1
- Glucagon-like peptide-1, an incretin hormone that reduces appetite, slows gastric emptying, and improves glucose control through glucose-dependent insulin secretion.
- GLP-1 agonist
- A compound that activates the GLP-1 receptor. Semaglutide is a pure, single-receptor GLP-1 agonist.
- Incretin
- A gut hormone, such as GLP-1 or GIP, released after eating that helps regulate insulin secretion and appetite.
- Titration
- Stepwise dose escalation over weeks to improve tolerability as exposure accumulates. Semaglutide's studied schedule runs 0.25 mg to 2.4 mg over roughly 16 to 20 weeks.
- Half-life
- The time for plasma concentration to fall by half. Semaglutide's roughly 7-day half-life supports once-weekly dosing.
- MACE
- Major adverse cardiovascular events, a composite outcome (cardiovascular death, non-fatal heart attack, non-fatal stroke) used in cardiovascular outcomes trials such as SUSTAIN-6.
- SNAC
- An absorption enhancer co-formulated with oral semaglutide that transiently protects a fraction of the dose from stomach acid and enzymatic breakdown long enough to be absorbed.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019;10:155.
- Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021;397(10278):971-984.
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375(19):1834-1844.
- Knop FK, et al. Oral semaglutide 50 mg taken once daily, for the treatment of overweight or obesity (OASIS 1). The Lancet. 2023;402(10403):705-719.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies of the semaglutide molecule, including the FDA-approved products Ozempic and Wegovy; cross-compound comparisons are drawn from separate trials, not head-to-head studies. The semaglutide discussed and sold here is supplied as a research compound, not as an approved pharmaceutical product, and is not intended for human use.